Abstract
Objective:
While gynaecological cancer patients who participate in Phase I clinical trials are not routinely considered for elective surgery because of a short life expectancy, this should not be overlooked in carefully selected responding patients.
Methods/results:
We describe two cases of patients with different gynaecological cancers, who received treatment within separate phase I trials, and who then proceeded to surgical resection of their cancers, resulting in complete remission.
Conclusion:
Surgery, when feasible, should be taken into consideration as a potential management option, even when patients are receiving treatment within a phase I trial.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adenocarcinoma, Papillary / drug therapy*
-
Adenocarcinoma, Papillary / secondary
-
Adult
-
Afatinib
-
Aged
-
Antibodies, Monoclonal, Humanized / administration & dosage
-
Antineoplastic Agents / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Bevacizumab
-
Carcinoma, Squamous Cell / drug therapy*
-
Carcinoma, Squamous Cell / secondary
-
Clinical Trials, Phase I as Topic*
-
Female
-
Humans
-
Liver Neoplasms / drug therapy*
-
Liver Neoplasms / secondary
-
Lung Neoplasms / drug therapy
-
Lung Neoplasms / secondary
-
Lung Neoplasms / surgery*
-
Lymph Node Excision
-
Lymphatic Metastasis
-
Ovarian Neoplasms / drug therapy*
-
Ovarian Neoplasms / pathology
-
Paclitaxel / administration & dosage
-
Pelvic Neoplasms / secondary
-
Pelvic Neoplasms / surgery*
-
Phthalazines / therapeutic use
-
Piperazines / therapeutic use
-
Quinazolines / administration & dosage
-
Uterine Cervical Neoplasms / drug therapy*
-
Uterine Cervical Neoplasms / pathology
Substances
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents
-
Phthalazines
-
Piperazines
-
Quinazolines
-
Bevacizumab
-
Afatinib
-
Paclitaxel
-
olaparib